Lakefront Biotherapeutics (LKFT) Net Income (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Income for 13 consecutive years, with $689600.3 the latest figure, recorded in Q1 2026.

• Quarterly Net Income fell 47.3% year-over-year to $689600.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $964985.2 (down 91.34% YoY) and the FY2025 annual result came in at $1.6 million, down 98.15% from the prior year.
• Net Income advanced to $689600.3 in Q1 2026 per LKFT's latest filing, from -$390318.3 in the prior quarter.
• Over the last five years, Net Income for LKFT reached as high as $225.0 million in Q4 2023 and fell as low as -$86.0 million in Q2 2022.
• A 5-year average of $6.9 million and a median of $689600.3 in 2026 frame the typical range for Net Income.
• Annual changes were most pronounced in 2022 — Net Income slumped 2304.9% — and 2023, when it surged 448.83%.
• Year by year, Net Income stood at -$76.4 million in 2022, then surged by 394.75% to $225.0 million in 2023, then sank by 96.87% to $7.0 million in 2024, then slumped by 105.55% to -$390318.3 in 2025, then jumped by 276.68% to $689600.3 in 2026.
• According to Business Quant data, Net Income over the past three periods registered $689600.3, -$390318.3, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.